Funding Received
$176.5 Million in 5 Rounds from 14 Investors
Most Recent Funding
$29.9 Million Series D on July 16, 2014
Founded:
2000
Headquarters:
Tübingen
Description:
immatics is a biopharmaceutical company focused on the development of immunotherapeutic substances for cancer therapy.
Categories:
Biotechnology
Website:
http://www.immatics.net

Detailed Description

Update

immatics is an independent biopharmaceutical company that focuses on the development of new immunotherapeutic substances for cancer therapy. The product can50 didates from immatics are based upon tumor-associated peptides (TUMAPs) that specifically stimulate the immune system against cancer cells. In September 2006 – and thus less than three years after the conclusion of the first round of funding totaling €14 million – the company successfully concluded an international clinical study on its product candidate IMA901 for combating renal cancer. Further product candidates, also consisting of peptide-based immuno55 therapeutic substances for cancer therapy, are presently undergoing preclinical development and will serve as the basis for a rapidly expanding product pipeline.

Past Team (1)

Update

Investors (14)

Update

Offices/Locations (1)

Update
  • Office

    Paul-Ehrlich-Str. 15

    Tübingen, 72076

    DEU

Images (1)

Update
  • 0927c1eb0246c26e527f04f2b7e5c49e